Literature DB >> 23440846

Behavioral interventions for improving contraceptive use among women living with HIV.

Laureen M Lopez1, Deborah Hilgenberg, Mario Chen, Julie Denison, Gretchen Stuart.   

Abstract

BACKGROUND: Contraception services can help meet the family planning goals of women living with HIV as well as prevent mother-to-child transmission. Due to the increased availability of antiretroviral therapy, survival has improved for people living with HIV, and more HIV-positive women may desire to have a child or another child. This review examines behavioral interventions to improve contraceptive use, for family planning, among women who are HIV-positive.
OBJECTIVES: We systematically reviewed studies that examined behavioral interventions for HIV-positive women that were intended to inform contraceptive choice, encourage contraceptive use, or promote adherence to a contraceptive regimen. SEARCH
METHODS: Through October 2012, we searched MEDLINE, CENTRAL, POPLINE, EMBASE, CINAHL, PsycINFO, ClinicalTrials.gov and ICTRP. For other relevant papers, we examined reference lists and unpublished project reports, and contacted investigators in the field. SELECTION CRITERIA: Studies evaluated a behavioral intervention for improving contraceptive use for contraception. The comparison could be another behavioral intervention, usual care, or no intervention. We also considered studies that compared HIV-positive women versus HIV-negative women. We included nonrandomized (observational) studies as well as randomized trials.Primary outcomes were pregnancy and contraception use, e.g., uptake of a new method, improved use or continuation of current method. Secondary outcomes were knowledge of contraceptive effectiveness and attitude about contraception in general or about a specific contraceptive method. DATA COLLECTION AND ANALYSIS: Two authors independently extracted the data. One author entered the data into RevMan and a second verified accuracy. We examined the quality of evidence using the Newcastle-Ottawa Quality Assessment Scale.Given the need to control for confounding factors in observational studies, we used adjusted estimates from the models when available. Where we did not have adjusted analyses, we calculated the odds ratio (OR) with 95% confidence interval (CI). Due to varied study designs, we did not conduct meta-analysis. MAIN
RESULTS: The seven studies meeting our inclusion criteria had a total of 8882 women. All were conducted in Africa. Three studies compared a special intervention versus standard services. In one, the special intervention site showed greater use of non-condom contraceptives per visit (OR 6.40; 95% CI 5.37 to 7.62) and reported a lower pregnancy incidence. In another study, use of modern contraceptives was more likely for women at sites with enhanced versus basic integrated services (OR 2.48; 95% CI 1.31 to 4.72), but the groups did not differ significantly in change from baseline. In the third study, new use of modern contraceptives, excluding condoms, was less likely for women with integrated services versus those with routine care (OR 0.56; 95% CI 0.42 to 0.75), but new use of condoms was more likely (OR 1.73; 95% CI 1.52 to 1.98).Four older studies compared HIV-positive women versus HIV-negative women. None showed any significant difference between the HIV-status groups in use of modern contraceptives. Two did not provide an intervention for the HIV-negative women. In the larger of the two studies, HIV-positive women were less likely to become pregnant (OR 0.55; 95% CI 0.43 to 0.69). HIV-positive women were more likely to discontinue their hormonal contraceptive (OR 2.52; 95% CI 1.53 to 4.14) but more likely to use condoms (OR 2.82; 95% CI 2.18 to 3.65) and spermicide (OR 2.36; 95% CI 1.69 to 3.30). Two studies provided the intervention to both HIV-status groups. One included many of the women from the study just mentioned, and also showed fewer pregnancies for HIV-positive women (OR 0.39; 95% CI 0.23 to 0.68). In the other study, the HIV-status groups were not significantly different for pregnancy or consistent condom use. AUTHORS'
CONCLUSIONS: Comparative research on contraceptive counseling for HIV-positive women has been limited. We found little innovation in the behavioral interventions. Our ability to make statements about overall results is hampered by varied study designs, interventions, and outcome assessments. The quality of evidence was moderate. Since some of these studies were conducted, improvements in HIV treatment have influenced the fertility intentions of HIV-positive people.The family planning field needs better ways to help women choose an appropriate contraceptive and continue using that chosen method. Women with HIV may have special concerns regarding family planning. Research could focus on assessing the woman's needs and training providers to address those issues rather than delivering standardized information.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23440846     DOI: 10.1002/14651858.CD010243.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  11 in total

1.  A systematic review of contraceptive continuation among women living with HIV.

Authors:  Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones
Journal:  Contraception       Date:  2018-02-09       Impact factor: 3.375

2.  Contraceptive Dynamics in Rural Northern Malawi: A Prospective Longitudinal Study.

Authors:  Aisha Nandini Zoe Dasgupta; Basia Zaba; Amelia C Crampin
Journal:  Int Perspect Sex Reprod Health       Date:  2015-09

3.  Implementation and Operational Research: A Time-Motion Analysis of HIV Transmission Prevention Counseling and Antiretroviral Adherence Messages in Western Kenya.

Authors:  Martin C Were; Jason Kessler; Changyu Shen; John Sidle; Stephen Macharia; John Lizcano; Abraham Siika; Kara Wools-Kaloustian; Ann Kurth
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

4.  Protocol for a systematic review on the effect of demand generation interventions on uptake and use of modern contraceptives in LMIC.

Authors:  Loubna Belaid; Alexandre Dumont; Nils Chaillet; Vincent De Brouwere; Amel Zertal; Sennen Hounton; Valéry Ridde
Journal:  Syst Rev       Date:  2015-09-28

5.  Integrating reproductive health services into HIV care: strategies for successful implementation in a low-resource HIV clinic in Lilongwe, Malawi.

Authors:  Sam Phiri; Caryl Feldacker; Thomas Chaweza; Linly Mlundira; Hannock Tweya; Colin Speight; Bernadette Samala; Fannie Kachale; Denise Umpierrez; Lisa Haddad
Journal:  J Fam Plann Reprod Health Care       Date:  2015-04-22

6.  CHARM, a gender equity and family planning intervention for men and couples in rural India: protocol for the cluster randomized controlled trial evaluation.

Authors:  Jennifer Yore; Anindita Dasgupta; Mohan Ghule; Madhusadana Battala; Saritha Nair; Jay Silverman; Niranjan Saggurti; Donta Balaiah; Anita Raj
Journal:  Reprod Health       Date:  2016-02-20       Impact factor: 3.223

7.  Prevalence and factors influencing modern contraceptive use among HIV-positive women in Kilimanjaro region, northern Tanzania.

Authors:  Damian J Damian; Johnston M George; Erick Martin; Beatrice Temba; Sia E Msuya
Journal:  Contracept Reprod Med       Date:  2018-05-22

8.  Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake.

Authors:  Lorna Begg; Rebecca Brodsky; Barbara Friedland; Sanyukta Mathur; Jim Sailer; George Creasy
Journal:  BMJ Sex Reprod Health       Date:  2020-07-31

Review 9.  Microbicides for the Treatment of Sexually Transmitted HIV Infections.

Authors:  Onkar Singh; Tarun Garg; Goutam Rath; Amit K Goyal
Journal:  J Pharm (Cairo)       Date:  2014-02-12

10.  Evaluation of Transtheoretical Model-Based Family Education Among Females of Zahedan (Southeast of Iran).

Authors:  Tahereh Kamalikhah; Fatemeh Rakhshani; Fatemeh Rahmati Najarkolaei; Mehdi Gholian Avval
Journal:  Iran Red Crescent Med J       Date:  2015-10-13       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.